BioStock: Elicera collaborates with US cancer centre to evaluate iTANK

Elicera Therapeutics is the sole biotech in Sweden developing CAR T-cell therapies. Beyond that, the company has developed a technology - the iTANK platform - with the potential to boost any T-cell receptor therapy – not just Elicera’s. This week, the company announced entering a Material Transfer Agreement with a prominent, still undisclosed, cancer centre based in the US to evaluate iTANK in a novel T-cell receptor therapy targeting skin cancer and lung cancer. BioStock caught up with Elicera’s CEO Jamal El-Mosleh to learn more.

Read the interview with Jamal El-Mosleh at biostock.se:

Elicera collaborates with US cancer centre to evaluate iTANK - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/